Loading…
MannKind Corporation is projected to rise to $3.64 by 2027, a +2% move from its current price of $3.55. MNKD is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $3.44 | $3.55 | $3.66 | -0.05% |
| May 30 | $3.39 | $3.55 | $3.71 | -0.11% |
| May 31 | $3.35 | $3.54 | $3.75 | -0.16% |
| Jun 1 | $3.32 | $3.54 | $3.78 | -0.22% |
| Jun 2 | $3.30 | $3.54 | $3.80 | -0.27% |
| Jun 3 | $3.27 | $3.54 | $3.83 | -0.33% |
| Jun 4 | $3.25 | $3.54 | $3.85 | -0.38% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $3.25 | $3.54 | $3.85 | -0.38% |
| Week 2 | $3.13 | $3.52 | $3.97 | -0.77% |
| Week 3 | $3.03 | $3.51 | $4.06 | -1.15% |
| Week 4 | $2.95 | $3.50 | $4.14 | -1.53% |
| Week 5 | $2.88 | $3.48 | $4.20 | -1.91% |
| Week 6 | $2.82 | $3.47 | $4.26 | -2.28% |
| Week 7 | $2.76 | $3.46 | $4.32 | -2.66% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
MannKind Corporation is a biopharmaceutical company that focuses on providing solutions for transforming chronic disease care. It develops and commercializes treatments addressing serious unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease. Its portfolio includes Afrezza inhalation powder, an inhaled insulin used to improve glycemic control in adults with diabetes; and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults.
Its products also include Tyvaso DPI for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; FUROSCIX, a furosemide injection to treat fluid buildup in patients with chronic heart failure or chronic kidney disease. The company's pipeline of treatments for orphan lung diseases includes MNKD-201, a dry-powder formulation of nintedanib for the treatment of idiopathic pulmonary fibrosis and MNKD-701. It has collaboration and license agreements with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; and collaboration with Thirona to evaluate a therapy for the treatment of pulmonary fibrosis.
MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.
MNKD trades at $3.38 per share and has a market cap of $1.04B, ranking 2515. It operates in the Healthcare sector as a public company focused on biopharmaceutical solutions for chronic diseases. The price outlook is indicated by a multi-year forecast showing growth in average prices from the 2026 level toward higher targets by 2030 and beyond, with the long-range forecast suggesting substantial upside potential in later years.
A major floor 35.8% below — a decisive break under it would weaken the trend.
The nearest floor, 25.9% below — buyers have tended to step in here.
Price is pressing into resistance (0.3% away) — a breakout level to watch.
A major ceiling 74.9% above — clearing it would confirm fresh momentum.
Key MNKD support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of MNKD market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $3.40 | Buy | $3.41 | Buy |
| MA 10 | $3.25 | Buy | $3.32 | Buy |
| MA 20 | $3.19 | Buy | $3.19 | Buy |
| MA 50 | $2.83 | Buy | $3.20 | Buy |
| MA 100 | $3.87 | Sell | $3.64 | Sell |
| MA 200 | $4.57 | Sell | $4.16 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 65.92 | Neutral |
| Stoch RSI (14) | 70.35 | Neutral |
| CCI (20) | 98.89 | Neutral |
| Williams %R (14) | 0.00 | Info |
| MACD (12,26,9) | 0.03 | Buy |
| ROC (12) | 0.85 | Buy |
| Bollinger %B (20,2) | 0.82 | Neutral |
| Stochastic %K (14) | 100.00 | Sell |
| TRIX (15) | 0.63 | Buy |
| Awesome (5,34) | 0.41 | Buy |
| Ultimate (7,14,28) | 70.16 | Sell |
| Momentum (10) | 0.27 | Buy |
| Aroon Osc (25) | 28.00 | Buy |
| Hull MA (9) | 3.57 | Sell |
| ADX (14) | 20.46 | Buy |
| ATR (14) | 0.10 | Info |
The near-term technical picture is bullish, with RSI(14) at 60. The stock is trading around key moving averages, with SMA50 at $2.80 and SMA200 at $4.57, and it sits near support of $2.63 and resistance of $3.56. The 30-day price range is $2.73 to $4.19, highlighting a volatile but upward-biased window in the short term.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $2.28 | $3.55 | $4.58 | 0% | Neutral | |
| $2.84 | $3.64 | $4.96 | +2% | Neutral | |
| $2.89 | $3.82 | $5.43 | +8% | Neutral | |
| $3.43 | $4.67 | $6.85 | +31% | Bullish | |
| $4.06 | $5.66 | $8.54 | +59% | Bullish | |
| $3.99 | $5.68 | $8.78 | +60% | Bullish | |
| $4.20 | $6.10 | $9.62 | +72% | Bullish | |
| $4.29 | $6.36 | $10.22 | +79% | Bullish | |
| $4.03 | $6.09 | $9.96 | +72% | Bullish | |
| $4.51 | $6.94 | $11.54 | +96% | Bullish | |
| $5.71 | $9.54 | $16.99 | +169% | Bullish | |
| $10.93 | $21.11 | $41.48 | +495% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $2.28 | $3.55 | $4.17 | +0.00% |
| June 2026 | $2.91 | $3.43 | $4.15 | -3.40% |
| July 2026 | $2.84 | $3.38 | $4.15 | -1.55% |
| August 2026 | $2.92 | $3.50 | $4.35 | +3.69% |
| September 2026 | $2.92 | $3.53 | $4.43 | +0.86% |
| October 2026 | $2.83 | $3.44 | $4.35 | -2.66% |
| November 2026 | $2.85 | $3.47 | $4.43 | +1.04% |
| December 2026 | $2.90 | $3.56 | $4.58 | +2.53% |
Click any year to see its month-by-month MNKD forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect MNKD to range from $2.28 to $4.58 through 2026. The $3.55 average target implies a 0% move from current prices. A consolidation phase looks the most probable path here.
The MNKD price prediction for 2027 points to an average of $3.64 (low $2.84, high $4.96) — a potential gain of +2% on today's $3.55. Price action looks broadly range-bound.
In 2028, MNKD is projected to trade between $2.89 and $5.43, averaging $3.82 — a potential gain of +8% from today's $3.55. That is up +5% on the projected 2027 average. A consolidation phase looks the most probable path here.
MannKind Corporation's 2029 outlook centres on $4.67, within a $3.43 to $6.85 range. That is up +22% on the projected 2028 average. That marks a +31% change versus current levels. Momentum favours further upside here.
By 2030, MNKD could reach as high as $8.54, with a base case around $5.66 and support toward $4.06 — roughly +59% from $3.55. Buyers look set to stay in control over this stretch.
Expect MNKD to range from $3.99 to $8.78 through 2031. The $5.68 average target implies a +60% move from current prices. That is up 0% on the projected 2030 average. Momentum favours further upside here.
The MNKD price prediction for 2032 points to an average of $6.10 (low $4.20, high $9.62) — a potential gain of +72% on today's $3.55. Buyers look set to stay in control over this stretch.
In 2033, MNKD is projected to trade between $4.29 and $10.22, averaging $6.36 — a potential gain of +79% from today's $3.55. That is up +4% on the projected 2032 average. Momentum favours further upside here.
MannKind Corporation's 2034 outlook centres on $6.09, within a $4.03 to $9.96 range. That is -4% versus the projected 2033 average. That marks a +72% change versus current levels. Buyers look set to stay in control over this stretch.
By 2035, MNKD could reach as high as $11.54, with a base case around $6.94 and support toward $4.51 — roughly +96% from $3.55. Momentum favours further upside here.
Expect MNKD to range from $5.71 to $16.99 through 2040. The $9.54 average target implies a +169% move from current prices. That is up +37% on the projected 2035 average. Buyers look set to stay in control over this stretch.
The MNKD price prediction for 2050 points to an average of $21.11 (low $10.93, high $41.48) — a potential gain of +495% on today's $3.55. Momentum favours further upside here.
Investing $1,000 in MNKD today (≈ 281.690141 MNKD) could be worth
$5,945.88
+$4,945.88 (+495%) by 2050 · US Dollar
Based on the average projected MNKD price of $21.11 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in MNKDwould be worth at today's price.
$1,000 invested in MNKD on May 27, 2025 (≈ 237.529689 MNKD) would be worth
$843.23
-$156.77 (-15.7%) today · 0.84× · US Dollar
Based on a MNKD entry price of $4.21 vs. today's $3.55.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $3.25 | $1,092.31 | +9.2% |
| 1 month ago | $2.63 | $1,349.81 | +35.0% |
| 3 months ago | $3.24 | $1,095.68 | +9.6% |
| 6 months ago | $5.35 | $663.55 | -33.6% |
| 1 year ago | $4.21 | $843.23 | -15.7% |
| All time (5.0y) ago | $4.04 | $878.71 | -12.1% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our MNKD forecast.
Our base-case forecast reaches $7.10 around 2040.
Implied market cap at $7.10: $2.19B
The multi-year forecast shows a path of higher values. For 2026 the avg price is $3.38 (min $2.28, max $4.35) and 2027 shows $3.38 (min $2.63, max $4.64), with 2028 at $3.59 (min $2.70, max $5.12) and 2029 at $4.31 (min $3.16, max $6.37). From 2030 onward, the avg price rises to $5.20 (min $3.71, max $7.88) in 2030, $5.27 (min $3.68, max $8.18) in 2031, $5.60 (min $3.83, max $8.89) in 2032, $5.79 (min $3.88, max $9.37) in 2033, $5.56 (min $3.65, max $9.15) in 2034, and $6.25 (min $4.03, max $10.47) in 2035, with ROI values of 53.8, 55.8, 65.8, 71.4, 64.4, and 85 respectively.
The forecast continues higher in later years, with 2040 avg $8.62 (ROI 155.1) and 2050 avg $18.72 (ROI 453.8), and a 2050 max of $37.13. These readings reflect a bullish sentiment in the longer horizon, though they are estimates and not guarantees.
Tap a question to reveal the answer.
The 2030 forecast shows an avg price of $5.20 with a min of $3.71 and a max of $7.88, and an ROI of 53.8.
The forecast indicates bullish sentiment from 2029 onward, with the average price rising to $18.72 by 2050 and a max of $37.13, but these are estimates, not guarantees.
Yes. The forecast for 2050 lists a max of $37.13.
The current price is $3.38 and the market cap is $1.04B.
The 30-day range is $2.73 to $4.19.
MannKind Corporation Community Discussion
0Share your MannKind Corporation price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.